187 related articles for article (PubMed ID: 25651476)
1. Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers.
Glue P; Winter H; Garbe K; Jakobi H; Lyudin A; Lenagh-Glue Z; Hung CT
J Clin Pharmacol; 2015 Jun; 55(6):680-7. PubMed ID: 25651476
[TBL] [Abstract][Full Text] [Related]
2. Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability.
Glue P; Lockhart M; Lam F; Hung N; Hung CT; Friedhoff L
J Clin Pharmacol; 2015 Feb; 55(2):189-94. PubMed ID: 25279818
[TBL] [Abstract][Full Text] [Related]
3. A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers.
Ruiz-Garcia A; Giri N; LaBadie RR; Ni G; Boutros T; Richie N; Kocinsky HS; Checchio TM; Bello CL
J Clin Pharmacol; 2014 May; 54(5):555-62. PubMed ID: 24293056
[TBL] [Abstract][Full Text] [Related]
4. Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet.
Kapil RP; Friedman K; Cipriano A; Michels G; Shet M; Mondal SA; Harris SC
Clin Ther; 2015 Oct; 37(10):2286-96. PubMed ID: 26350273
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients.
Knuijver T; Ter Heine R; Schellekens AFA; Heydari P; Lucas L; Westra S; Belgers M; van Oosteren T; Verkes RJ; Kramers C
J Psychopharmacol; 2024 May; 38(5):481-488. PubMed ID: 38519421
[TBL] [Abstract][Full Text] [Related]
6. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
[TBL] [Abstract][Full Text] [Related]
7. Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures.
Mash DC; Kovera CA; Pablo J; Tyndale RF; Ervin FD; Williams IC; Singleton EG; Mayor M
Ann N Y Acad Sci; 2000 Sep; 914():394-401. PubMed ID: 11085338
[TBL] [Abstract][Full Text] [Related]
8. The effect of potent CYP2D6 inhibition on the pharmacokinetics and safety of deutetrabenazine in healthy volunteers.
Schneider F; Stamler D; Bradbury MJ; Loupe PS; Gordon MF; Rabinovich-Guilatt L
Eur J Clin Pharmacol; 2022 Jan; 78(1):11-18. PubMed ID: 34491372
[TBL] [Abstract][Full Text] [Related]
9. Ascending Single-Dose, Double-Blind, Placebo-Controlled Safety Study of Noribogaine in Opioid-Dependent Patients.
Glue P; Cape G; Tunnicliff D; Lockhart M; Lam F; Hung N; Hung CT; Harland S; Devane J; Crockett RS; Howes J; Darpo B; Zhou M; Weis H; Friedhoff L
Clin Pharmacol Drug Dev; 2016 Nov; 5(6):460-468. PubMed ID: 27870477
[TBL] [Abstract][Full Text] [Related]
10. How toxic is ibogaine?
Litjens RP; Brunt TM
Clin Toxicol (Phila); 2016; 54(4):297-302. PubMed ID: 26807959
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems.
Chen R; Wang H; Shi J; Shen K; Hu P
Eur J Clin Pharmacol; 2015 Jul; 71(7):835-41. PubMed ID: 25967538
[TBL] [Abstract][Full Text] [Related]
12. Noribogaine generalization to the ibogaine stimulus: correlation with noribogaine concentration in rat brain.
Zubaran C; Shoaib M; Stolerman IP; Pablo J; Mash DC
Neuropsychopharmacology; 1999 Jul; 21(1):119-26. PubMed ID: 10379526
[TBL] [Abstract][Full Text] [Related]
13. Effects of low dose ibogaine on subjective mood state and psychological performance.
Forsyth B; Machado L; Jowett T; Jakobi H; Garbe K; Winter H; Glue P
J Ethnopharmacol; 2016 Aug; 189():10-3. PubMed ID: 27180314
[TBL] [Abstract][Full Text] [Related]
14. Paroxetine markedly increases plasma concentrations of ophthalmic timolol; CYP2D6 inhibitors may increase the risk of cardiovascular adverse effects of 0.5% timolol eye drops.
Mäenpää J; Volotinen-Maja M; Kautiainen H; Neuvonen M; Niemi M; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2014 Dec; 42(12):2068-76. PubMed ID: 25261563
[TBL] [Abstract][Full Text] [Related]
15. In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats.
Baumann MH; Rothman RB; Pablo JP; Mash DC
J Pharmacol Exp Ther; 2001 May; 297(2):531-9. PubMed ID: 11303040
[TBL] [Abstract][Full Text] [Related]
16. Acute toxicity of ibogaine and noribogaine.
Kubiliene A; Marksiene R; Kazlauskas S; Sadauskiene I; Razukas A; Ivanov L
Medicina (Kaunas); 2008; 44(12):984-8. PubMed ID: 19142057
[TBL] [Abstract][Full Text] [Related]
17. A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects.
Tsukada H; Chen YL; Xiao G; Lennek L; Milanovic SM; Worden M; Polhamus DG; Chiu YY; Hopkins SC; Galluppi GR
Clin Pharmacokinet; 2023 Dec; 62(12):1755-1763. PubMed ID: 37882999
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects.
Lim KS; Cho JY; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Shin SG; Yu KS
Br J Clin Pharmacol; 2008 Nov; 66(5):660-6. PubMed ID: 18754843
[TBL] [Abstract][Full Text] [Related]
20. Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different CYP2D6 genotypes.
Jung EH; Lee YJ; Kim DH; Kang P; Lim CW; Cho CK; Jang CG; Lee SY; Bae JW
Arch Pharm Res; 2020 Dec; 43(12):1356-1363. PubMed ID: 33245517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
